Overview

BIIB014 Phase 2a Monotherapy

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To assess the preliminary safety and tolerability of multiple oral doses of BIIB014 in subjects with early PD.
Phase:
Phase 2
Details
Lead Sponsor:
Biogen
Treatments:
3-(4-amino-3-methylbenzyl)-7-(2-furyl)-3H-(1,2,3)triazolo(4,5-d)pyrimidine-5-amine